BioCentury | Jan 4, 2016
Financial News

GenSpera completes private placement of convertible preferred stock and warrants

GenSpera Inc. (OTCQB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 2015-12-23 Type: Private placement of convertible preferred stock and warrants Raised: $1.9 million Shares: 1,853 Price: $1,000 Shares outstanding prior: 37.5 million Placement agent: H.C....
BioCentury | Jan 4, 2016
Financial News

GenSpera completes warrant exercise

...Price: $0.15 Shares outstanding prior: 37.5 million Placement agent: H.C. Wainwright Investor: Institutional investors Note: GenSpera...
BioCentury | Jul 13, 2015
Financial News

GenSpera completes private placement of common stock and warrants

GenSpera Inc. (OTCQB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 2015-07-06 Type: Private placement of common stock and warrants Raised: $2.5 million Shares: 3.6 million Price: $0.70 Shares after offering: 37.1 million Placement agent: H.C....
BioCentury | Jan 26, 2015
Clinical News

Mipsagargin: Phase II data

...GenSpera said it designing a Phase III trial to evaluate mipsagargin in liver cancer patients. GenSpera Inc....
BioCentury | Oct 20, 2014
Clinical News

Mipsagargin: Completed Phase II enrollment

...Onyx Pharmaceuticals Inc. , now part of Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.), market Nexavar. GenSpera Inc....
BioCentury | Sep 29, 2014
Clinical News

Mipsagargin: Interim Phase Ib/II data

...G-202 is also in a Phase II trial to treat glioblastoma multiforme (GBM). Next quarter, GenSpera...
...Onyx Pharmaceuticals Inc. , now part of Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.), market Nexavar. GenSpera Inc....
BioCentury | Jun 2, 2014
Financial News

GenSpera completes direct public offering

GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 5/29/14 Type: Direct public offering Raised: $3.3 million Units: 4.2 million Price: $0.80 (unit) Shares after offering: 31.6 million Placement agent: H.C. Wainwright Note: Each...
BioCentury | Mar 24, 2014
Clinical News

G-202: Phase II started

...advanced, progressive hepatocellular carcinoma (HCC), for which it has Orphan Drug designation in the U.S. GenSpera Inc....
BioCentury | Sep 2, 2013
Financial News

GenSpera completes private placement of units

GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 8/19/13 Type: Private placement of units Raised: $5 million Units: 3.3 million Price: $1.50 (unit) Shares after offering: 27.2 million Placement agent: T.R. Winston Investors:...
BioCentury | Mar 18, 2013
Clinical News

G-202 regulatory update

...prodrug of plant-derived cytotoxin 12ADT is in Phase II testing to treat advanced, progressive HCC. GenSpera Inc....
Items per page:
1 - 10 of 20
BioCentury | Jan 4, 2016
Financial News

GenSpera completes private placement of convertible preferred stock and warrants

GenSpera Inc. (OTCQB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 2015-12-23 Type: Private placement of convertible preferred stock and warrants Raised: $1.9 million Shares: 1,853 Price: $1,000 Shares outstanding prior: 37.5 million Placement agent: H.C....
BioCentury | Jan 4, 2016
Financial News

GenSpera completes warrant exercise

...Price: $0.15 Shares outstanding prior: 37.5 million Placement agent: H.C. Wainwright Investor: Institutional investors Note: GenSpera...
BioCentury | Jul 13, 2015
Financial News

GenSpera completes private placement of common stock and warrants

GenSpera Inc. (OTCQB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 2015-07-06 Type: Private placement of common stock and warrants Raised: $2.5 million Shares: 3.6 million Price: $0.70 Shares after offering: 37.1 million Placement agent: H.C....
BioCentury | Jan 26, 2015
Clinical News

Mipsagargin: Phase II data

...GenSpera said it designing a Phase III trial to evaluate mipsagargin in liver cancer patients. GenSpera Inc....
BioCentury | Oct 20, 2014
Clinical News

Mipsagargin: Completed Phase II enrollment

...Onyx Pharmaceuticals Inc. , now part of Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.), market Nexavar. GenSpera Inc....
BioCentury | Sep 29, 2014
Clinical News

Mipsagargin: Interim Phase Ib/II data

...G-202 is also in a Phase II trial to treat glioblastoma multiforme (GBM). Next quarter, GenSpera...
...Onyx Pharmaceuticals Inc. , now part of Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.), market Nexavar. GenSpera Inc....
BioCentury | Jun 2, 2014
Financial News

GenSpera completes direct public offering

GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 5/29/14 Type: Direct public offering Raised: $3.3 million Units: 4.2 million Price: $0.80 (unit) Shares after offering: 31.6 million Placement agent: H.C. Wainwright Note: Each...
BioCentury | Mar 24, 2014
Clinical News

G-202: Phase II started

...advanced, progressive hepatocellular carcinoma (HCC), for which it has Orphan Drug designation in the U.S. GenSpera Inc....
BioCentury | Sep 2, 2013
Financial News

GenSpera completes private placement of units

GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Business: Cancer Date completed: 8/19/13 Type: Private placement of units Raised: $5 million Units: 3.3 million Price: $1.50 (unit) Shares after offering: 27.2 million Placement agent: T.R. Winston Investors:...
BioCentury | Mar 18, 2013
Clinical News

G-202 regulatory update

...prodrug of plant-derived cytotoxin 12ADT is in Phase II testing to treat advanced, progressive HCC. GenSpera Inc....
Items per page:
1 - 10 of 20